David Eveleth

David Eveleth is the current CEO at Trefoil Therapeutics. Prior to this, they were the President, CEO and Founder at CavtheRx, Inc. from November 2014 to October 2016.

CavtheRx, Inc. is a company that develops a novel therapy for autoimmune diseases including multiple sclerosis, inflammatory bowel disease, uveitis, neuromyelitis optica, and other conditions together representing a >$20 billion dollar market. The platform technology is a mechanistic approach to inhibit the passage of inflammatory cells and inflammatory signals across the vascular endothelium through modulation of caveolin function. This technology was developed by Dr William Sessa at Yale University and has been shown to be effective in a wide variety of disease models including models of uveitis, multiple sclerosis, inflammatory bowel disease, age-related macular degeneration, cancer, pulmonary fibrosis, and peripheral inflammation.

CavtheRx has a licensing agreement with Yale University for the core technology with the scientific and business approach validated by the award of NIH grants and a seed investment. CavtheRx is developing these molecules in orphan and high unmet need indications using a capital efficient development program followed by expansion into the larger markets.

Under David's leadership, CavtheRx has made significant progress in developing their novel therapy and expanding into new markets. Their experience in the biotech industry has been invaluable in helping the company grow and develop their innovative platform.

David Eveleth has a PhD in Biology from UC Irvine and a BS in Biology from the University of Connecticut.

Schalon Newton - Chief Business Officer, Thomas M. Tremblay - VP, Clinical Development report to David Eveleth.